Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Potential Benefits of RSV Vaccine Approval for Adults Aged 50-59
As phase 3 data for the RSV vaccine are leading the FDA to consider expanding the age range to include patients aged 50-59, the panel discusses the potential clinical and economic benefits.
EP: 1.Overview of RSV Patient Populations
EP: 2.Complications Associated with RSV Infections
EP: 3.The Economic Burden and Main Drivers of Healthcare Resource Utilization in RSV
EP: 4.RSV: Risk Factors and How It’s Spread
EP: 5.Diagnostic Practices for RSV
EP: 6.Increasing Awareness of RSV Vaccines in At-Risk Patients
EP: 7.Shared Decision-Making Practices in RSV
EP: 8.Financial and Clinical Benefits of RSV Immunization
Now Viewing
EP: 9.The Potential Benefits of RSV Vaccine Approval for Adults Aged 50-59
EP: 10.Addressing Vaccine Fatigue
EP: 11.Identifying Patients Eligible for RSV Vaccine
EP: 12.Current and Potential Obstacles Related to Administering RSV Vaccines
EP: 13.Improving Insurance Coverage for RSV Vaccines
EP: 14.Improving RSV Vaccination Rates and Addressing Misinformation
EP: 15.Key Takeaways on RSV Vaccination
Video content above is prompted by the following questions:
- What is the important phase 3 data for the RSV vaccine that is leading the FDA to consider an expanded age range to 50-59?
- How would RSV vaccine approval for adults aged 50-59 improve the clinical and economic impact of the disease?
- What will the best practices be for identifying patients who are eligible for receiving the RSV vaccine with the potential updated indication?
- How should payers adjust coverage decisions for RSV vaccines in patients aged 50-59 if this expanded indication is approved?
- How should the ACIP/CDC incorporate a potential indication expansion into their recommendations?
- How should the ACIP/CDC incorporate a potential indication expansion into their recommendations?
Related Videos
Related Content
Infant RSV Hospitalization Rates Drop in First Season With Widespread Preventive Product Use
May 14th 2025Article
New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the importance of timely vaccination and nirsevimab administration.
Read More
